Morphine decreases ticagrelor concentrations but not its antiplatelet effects: A randomized trial in healthy volunteers

European Journal of Clinical Investigation

Volumn 46, Issue 1, 2016, Pages 7-14

  Hobl, Eva Luise ^a   Reiter, Birgit ^a   Schoergenhofer, Christian ^a   Schwameis, Michael ^a   Derhaschnig, Ulla ^a   Kubica, Jacek ^b   Stimpfl, Thomas ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Drug interaction; Morphine; Multiple electrode aggregometry; Platelet function analyser; Ticagrelor; Vasodilator stimulated phosphoprotein

Indexed keywords

DRUG METABOLITE; MORPHINE; MORPHINE SULFATE; PLACEBO; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; NARCOTIC ANALGESIC AGENT; PHOSPHOPROTEIN; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TINGLING; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; THROMBOCYTE; YOUNG ADULT;

ADENOSINE; ADULT; ANALGESICS, OPIOID; BLOOD PLATELETS; CELL ADHESION MOLECULES; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MICROFILAMENT PROTEINS; MORPHINE; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84955203233     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12550     Document Type: Article

References (36)

1. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-41.
2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425.
3. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106:1622-6.
4. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
5. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32.
6. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
7. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601-6.
8. Conti CR. Intravenous morphine and chest pain. Clin Cardiol 2011;34:464-5.
9. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005;149:1043-9.
10. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Urban D et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol 2015;104:727-34.
11. Nimmo WS, Heading RC, Wilson J, Tothill P, Prescott LF. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol 1975;2:509-13.
12. Alexopoulos D, Bhatt DL, Hamm CW, Steg PG, Stone GW. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J 2015;170:3-12.
13. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
14. Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014;63:630-5.
15. Abell LM, Liu EC. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. J Pharmacol Exp Ther 2011;339:589-96.
16. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. The Journal of Clinical Pharmacology 2010;50:126-42.
17. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation 2013;127:673-80.
18. Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011;162:160-5.
19. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85.
20. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010;8:351-9.
21. Siller-Matula JM, Gruber C, Francesconi M, Dechant C, Jilma B, Delle-Karth G et al. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clinical Science (London, England: 1979) 2015;128:121-30.
22. Hobl EL, Derhaschnig U, Firbas C, Schoergenhofer C, Schwameis M, Jilma B. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor. Eur J Clin Invest 2013;43:1258-61.
23. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-52.
24. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-52.
25. Hobl EL, Jilma B, Derhaschnig U, Schoergenhofer C, Schwameis M, Jilma-Stohlawetz P. Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y -inhibition after ticagrelor intake. Cytometry. Part B, Clinical cytometry 2015;88:385-8.
26. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clinical Science (London, England: 1979) 2012;123:591-600.
27. Spiel AO, Bartko J, Schwameis M, Firbas C, Siller-Matula J, Schuetz M et al. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial. Thromb Haemost 2011;105:655-62.
28. Spiel AO, Siller-Matula J, Firbas C, Leitner JM, Russmueller G, Jilma B. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans. Platelets 2010;21:464-9.
29. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007;81:298-304.
30. Braun OO, Johnell M, Varenhorst C, James S, Brandt JT, Jakubowski JA et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008;100:626-33.
31. Montalescot G, van't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014;371:1016-27.
32. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. Cardiovascular Interventions 2015;8:e001593.
33. Kim YI, Williams JF Jr. Large dose sublingual nitroglycerin in acute myocardial infarction: relief of chest pain and reduction of Q wave evolution. The American Journal of Cardiology 1982;49:842-8.
34. Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983;67:I32-41.
35. Bochner F, Lloyd JV. Aspirin for myocardial infarction. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1995;28:433-8.
36. Hobl EL, Schmid RW, Stimpfl T, Ebner J, Jilma B. Absorption kinetics of low-dose chewable aspirin-implications for acute coronary syndromes. Eur J Clin Invest 2015;45:13-7.